A. Menarini Diagnostics and Nucleix Join Forces for Bladder Cancer Innovation
A. Menarini Diagnostics is making a significant advancement in cancer care by announcing its exclusive marketing rights for the non-invasive Bladder EpiCheck test in Europe. This innovative test offers a straightforward urine analysis aimed at detecting and monitoring the recurrence of bladder cancer.
Strategic Partnership for Improved Cancer Detection
In a recent development, A. Menarini Diagnostics and Nucleix established a long-term commercial agreement to distribute the Bladder EpiCheck test, a collaboration highlighted at a prominent European congress on pathology. This partnership reflects their shared dedication to enhancing healthcare through cutting-edge diagnostic solutions.
What is the Bladder EpiCheck Test?
The Bladder EpiCheck test is a CE-marked, non-invasive diagnostic tool designed to identify both primary and recurrent bladder cancer, as well as upper tract urinary cancer. It is included in stringent clinical guidelines as a viable alternative to traditional cystoscopic procedures, making cancer monitoring less invasive and more patient-friendly.
The Significance of Bladder Cancer Monitoring
Bladder cancer is the sixth most common cancer in Europe, currently affecting around 760,000 individuals. Ongoing monitoring is crucial, particularly for patients with non-muscle invasive bladder cancer (NMIBC), who face high recurrence rates. The Bladder EpiCheck test enhances non-invasive monitoring, potentially reducing the need for frequent invasive procedures and aiming to improve overall patient outcomes.
Leadership Endorsement
Chris Hibberd, Executive Chairman and CEO of Nucleix, expressed his excitement about this collaboration, highlighting A. Menarini Diagnostics' extensive market reach and their role in transforming bladder cancer care through advanced decision-making support for healthcare professionals.
A Commitment to Patient-Centric Solutions
Fabio Piazzalunga, General Manager and Global Head of Menarini Diagnostics, emphasized that this strategic agreement is crucial for expanding access to non-invasive testing options for patients throughout Europe, reinforcing their commitment to innovation in the diagnostics sector.
About Nucleix
Nucleix is a leader in liquid biopsy technology, dedicated to the early detection of cancer. Their mission focuses on improving intervention timing and enhancing patient outcomes. By utilizing advanced methodologies, Nucleix provides highly sensitive results through its innovative EpiCheck tests.
About A. Menarini Diagnostics
A. Menarini Diagnostics has been at the forefront of developing advanced in vitro diagnostic solutions for over 45 years. Their commitment to innovation empowers healthcare professionals to make informed diagnoses, ultimately improving quality of life worldwide.
Frequently Asked Questions
What is the Bladder EpiCheck test?
The Bladder EpiCheck test is a non-invasive urine test designed to detect primary and recurrent bladder cancer, as well as upper tract urinary cancer.
Why is this partnership significant?
This partnership aims to enhance patient care in bladder cancer by increasing access to non-invasive diagnostic solutions across Europe.
How does Bladder EpiCheck improve patient outcomes?
This test minimizes the need for frequent cystoscopies, making monitoring less invasive and more comfortable while allowing for earlier identification of patients who may require further intervention.
Who are Nucleix and A. Menarini Diagnostics?
Nucleix specializes in liquid biopsy technology focused on early cancer detection, while A. Menarini Diagnostics develops innovative diagnostic solutions for healthcare professionals.
What makes this test reliable?
Bladder EpiCheck is CE-marked and adheres to strict clinical guidelines, ensuring its reliability in diagnosing and monitoring bladder cancer.
